[1] |
熊裕民, 王治伟, 金鑫, 等. 乳腺癌组织转移相关蛋白-3表达与腋窝淋巴结转移的相关性[J]. 检验医学, 2019, 34(3):206-210.
|
[2] |
钟鸣, 刘英霞, 翁剑华, 等. 乳腺癌腋窝淋巴结转移的危险因素[J]. 热带医学杂志, 2018, 18(1):43-46.
|
[3] |
顾晓东, 苏江, 邵正才, 等. 影响乳腺癌腋窝淋巴结转移的术前因素[J]. 重庆理工大学学报(自然科学版), 2017, 31(12):136-139.
|
[4] |
周成香, 刘亚斌, 查晓霞, 等. 高频彩色多普勒超声对乳腺癌腋窝淋巴结性质的鉴别价值[J]. 现代生物医学进展, 2017, 17(13):2565-2568.
|
[5] |
褚巍, 杨沪, 宋燕, 等. 高频彩色多普勒超声早期诊断乳腺癌腋窝淋巴结转移的临床应用价值[J]. 癌症进展, 2018, 16(3):309-311.
|
[6] |
仲维兰, 鲁美钰, 司春枫, 等. 乳腺癌靶向治疗研究进展[J]. 现代肿瘤医学, 2018, 26(4):622-626.
|
[7] |
CASCIATO D A. 临床肿瘤手册[M]. 朱广卿,王伟夫,译. 7版. 北京: 科学出版社, 2015.
|
[8] |
COATES A S, WINER E P, GOLDHIRSCH A, et al. Tailoring therapies-improving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol, 2015, 26(8):1533-1546.
DOI
URL
|
[9] |
高静, 谢玮, 俞敏. 程序性细胞死亡因子5(PDCD5)在子宫内膜癌中的表达分析[J]. 甘肃科学学报, 2017, 29(5):82-84.
|
[10] |
王巍, 张志常, 邵跃, 等. 利用GOBO软件分析PDCD5在乳腺癌中的表达和预后[J]. 解剖科学进展, 2017, 23(3):291-292.
|
[11] |
刘宏峰, 张彩虹, 张秀芳, 等. PDCD5通过Wnt/β-catenin通路抑制肾细胞癌侵袭转移及其机制研究[J]. 中国医药生物技术, 2018, 13(3):232-237.
|
[12] |
田景中, 李光云, 许建国, 等. 奥沙利铂对胃癌凋亡相关蛋白PDCD5和XIAP表达影响研究[J]. 中华肿瘤防治杂志, 2018, 25(6):384-388.
|
[13] |
CHEN Y, LIU Y, WANG Y, et al. Quantification of STAT3 and VEGF expression for molecular diagnosis of lymph node metastasis in breast cancer[J]. Medicine(Baltimore), 2017, 96(45):e8488.
|
[14] |
戴维德, 马娜, 王川予, 等. 超声引导细针穿刺样本BRAF V600E及CyclinD1联合检测对于甲状腺癌患者颈部淋巴结转移的预测价值[J]. 山西医科大学学报, 2017, 48(6):589-592.
|
[15] |
WANG L, WANG C, SU B, et al. Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo[J]. Biochem Cell Biol, 2013, 91(6):526-531.
DOI
URL
|
[16] |
DENG M, ZENG C, LU X, et al. MiR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop[J]. Cancer Lett, 2017, 403:175-185.
DOI
URL
|
[17] |
ZHAO L, LIU L, DONG Z, et al. MiR-149 suppresses human non-small cell lung cancer growth and metastasis by inhibiting the FOXM1/cyclin D1/MMP2 axis[J]. Oncol Rep, 2017, 38(6):3522-3530.
|
[18] |
KO G H, GO S I, LEE W S, et al. Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation[J]. Medicine(Baltimore), 2017, 96(25):e7181.
|
[19] |
YOUSEF E M, FURRER D, LAPERRIERE D L, et al. MCM2:an alternative to Ki-67 for measuring breast cancer cell proliferation[J]. Mod Pathol, 2017, 30(5):682-697.
DOI
URL
|
[20] |
燕国丽, 胡作为, 成薇婷. miR-3168靶向PDCD5调控A549细胞凋亡[J]. 中国免疫学杂志, 2019, 35(18):2181-2186.
|
[21] |
CAIAZZO C, DI MICCO R, ESPOSITO E, et al. The role of MRI in predicting Ki-67 in breast cancer:preliminary results from a prospective study[J]. Tumori, 2018, 104(6):438-443.
DOI
URL
|
[22] |
刘卓, 李晓凤, 张美云. Apaf-1和Ki-67在乳腺癌组织中的表达及临床意义[J]. 临床肿瘤学杂志, 2017, 22(2):133-136.
|
[23] |
MEI H X, ZHOU M H, ZHANG X W, et al. Effects of miR-338 on morphine tolerance by targeting CXCR4 in a rat model of bone cancer pain[J]. Biosci Rep, 2017, 37(2):BSR20160517.
|
[24] |
徐娟, 吴诚龙, 赖带欢, 等. TPST1表达在CXCR4诱导的乳腺癌细胞侵袭中的作用研究[J]. 激光生物学报, 2018, 27(5):435-441.
|
[25] |
胥丹, 姜淮芜, 蒲羽. 靶向PDCD5-Caspase-3融合基因过表达对HepG2肝癌细胞增殖与凋亡的影响[J]. 中国现代医学杂志, 2018, 28(24):22-26.
|
[26] |
郝克, 吕晓兰, 侯敏. 卵巢癌淋巴结转移患者治疗有效率与超声造影定量分析指标和E-cadherin、Vimentin表达的相关性分析[J]. 解放军预防医学杂志, 2018, 36(A01):4.
|
[27] |
LEFORT S, THULEAU A, KIEFFER Y, et al. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients[J]. Oncogene, 2017, 36(9):1211-1222.
DOI
URL
|
[28] |
KWAK S, LEE S H, HAN E J, et al. Serine/threonine kinase 31 promotes PDCD5-mediated apoptosis in p53- dependent human colon cancer cells[J]. J Cell Physiol, 2019, 234(3):2649-2658.
DOI
URL
|
[29] |
GAO F, ZHAO M, HUANG S, et al. Clinicopathological significance of decreased expression of the tumor inhibitor gene PDCD5 in osteoclastoma[J]. Genet Test Mol Biomarkers, 2019, 23(11):807-814.
DOI
URL
|